英文字典中文字典51ZiDian.com

中文字典辞典英文字典 a b c d e f g h i j k l m n o p q r s t u v w x y z

whereto

ad. 何以,向何处,为什么

何以,向何处,为什?

The Collaborative International Dictionary of English v.0.48 (gcide)

Whereto \Where*to"\, adv.
[1913 Webster]
1. To which; -- used relatively. "Whereto we have already
attained." --Phil. iii. 16.
[1913 Webster]

Whereto all bonds do tie me day by day. --Shak.
[1913 Webster]

2. To what; to what end; -- used interrogatively.
[1913 Webster]

请选择你想看的字典辞典：

单词	字典	翻译
whereto	查看　whereto　在百度字典中的解释	百度英翻中〔查看〕
whereto	查看　whereto　在Google字典中的解释	Google英翻中〔查看〕
whereto	查看　whereto　在Yahoo字典中的解释	Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!

中文字典英文字典工具:

选择颜色:

<style type="text/css">#word104_1 br {display:none;}</style>
<form id="word104_1" method="post" action="http://no.goldgoldprice.com/index.php" target="_blank">
<div style="width: 140px;border:1px solid #000;background-color:#ffffff;padding: 0px 0px;margin: 0px 0px;align:center;text-align:center;overflow:hidden;"><div id="xcolor1_1" style="font-size:12px;color:#183a00;line-height:16px;font-family: arial; font-weight:bold;background:#94abf0;padding: 3px 1px;text-align:center;"><a href="http://no.goldgoldprice.com/" alt="英文字典中文字典" title="英文字典中文字典" id="word_name104_1" style="color:#000000;font-size:14px;text-decoration:none;line-height:16px;font-family: arial;" >英文字典中文字典</a></div><table width=100% style='align:center;text-align:left;font-size:12px;background-color:#ffffff;color:#333333;'>
<tr><td style="text-align:center;border:0"><input type=hidden name="word104_hi" value="1">输入中英文单字</td></tr><tr><td style="text-align:center;border:0"><input type="text" name="word104_input" value="" size=10 style="background-color:#ffffff;color:#000;text-decoration:none;font-family: arial;rial;border:1px solid #999;padding:1px!important;"></td></tr><tr style='line-height: 26px;'><td style="text-align:center;border:0"><input type=submit style="background-color:#ccc;color:#000;border:0 none;cursor:pointer;" value="查询字典"></td></tr></table></div>
</form>

英文字典中文字典相关资料:

Avalo
Avalo is a clinical-stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases Our lead asset, abdakibart (AVTX-009), is in a Phase 2 clinical trial for hidradenitis suppurativa (HS) We’re also exploring additional opportunities to make an impact in prevalent indications that have significant remaining unmet needs Developing
Avalo
At Avalo, we’re 100% focused on developing treatments for immune-mediated inflammatory diseases with large unmet needs that affect millions worldwide Our strategy is to develop medicines that target the IL-1β pathway, which is a central driver of the inflammatory process Our lead asset, abdakibart (AVTX-009), is an anti-IL-1β monoclonal antibody currently being studied in a Phase 2 trial
Avalo Therapeutics, Inc. (AVTX)
Avalo (AVTX) is a clinical stage biotechnology company focused on the treatment of immune mediated inflammatory diseases Avalo’s lead asset is AVTX-009, an anti-IL-1β mAb, targeting inflammatory diseases
Avalo
Progressing product candidates targeting immune-mediated inflammatory diseases We are advancing a pipeline that emphasizes a high-value, potentially best-in-class and best-in-disease biologic for an immune-mediated inflammatory disease Our lead asset, abdakibart (AVTX-009) , is a high affinity, highly potent humanized IgG monoclonal antibody (mAb) designed to specifically inhibit IL-1β and
Avalo Therapeutics Expands Leadership Team with Key Appointments in . . .
WAYNE, Pa , Oct 01, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced the expansion of its leadership team with two senior appointments: Taylor Boyd has been named Chief Business Officer, and Ashley Ivanowicz has joined as
Avalo Therapeutics Announces Completion of Enrollment in Phase 2 LOTUS . . .
About Avalo Therapeutics Avalo Therapeutics is a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases Our lead asset, AVTX-009, is in a Phase 2 clinical trial for hidradenitis suppurativa (HS)
Avalo Therapeutics Reports Third Quarter 2025 Financial Results and . . .
WAYNE, Pa , Nov 06, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced business updates and financial results for the third quarter of 2025
Avalo Reports Second Quarter 2025 Financial Results and Recent Business . . .
WAYNE, Pa , Aug 07, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced business updates and financial results for the second quarter of 2025
Avalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing . . .
About Avalo Therapeutics Avalo Therapeutics is a clinical stage biotechnology company focused on the treatment of immune dysregulation Avalo’s lead asset is AVTX-009, an anti-IL-1β mAb, targeting inflammatory diseases Avalo’s pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein)
Press Releases :: Avalo Therapeutics, Inc. (AVTX)
Avalo Therapeutics Announces Completion of Enrollment in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis Suppurativa

中文字典-英文字典 2005-2009